Page 3 - Anders Ullman News Today

/PRNewswire/ -- Sobi® today announced that the US Food and Drug Administration has granted Emergency Use Authorisation (EUA) for the use of Kineret® (anakinra)...

STOCKHOLM, Nov. 10, 2022 /PRNewswire/ -- Sobi® today announced that the US Food and Drug Administration has...

STOCKHOLM, Nov. 10, 2022 /PRNewswire/ -- Sobi today announced that the US Food and Drug Administration has granted Emergency Use Authorisation (EUA) for the use of Kineret (anakinra) for the

Approval decision expected in 4Q 2022 ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European

STOCKHOLM, Sept. 16, 2022 /PRNewswire/ -- Sobi and ADC Therapeutics SA today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted

Annualised bleed rate (ABR), injection frequency and factor consumption were significantly lower compared to standard half-life (SHL) FVIII prophylaxis Results demonstrated the superior

Congress in London, demonstrating improved prophylactic effectiveness in Elocta® (efmoroctocog alfa) treated...

Annualised bleed rate among haemophilia A patients was significantly lower in real-world setting - News - PharmaTimes

Investigational once-weekly efanesoctocog alfa prophylaxis met the primary efficacy endpoint providing clinically meaningful bleed protection for people with severe hemophilia AResults underscore the ability of efanesoctocog alfa to sustain normal to near-normal factor levels and the potential to transform prophylac...

Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis Investigational once-weekly efanesoctocog alfa prophylaxis met the